APA

Blake D. R., Vaseva A. V., Hodge R. G., Kline M. P., Gilbert T. S. K., Tyagi V., Huang D., Whiten G. C., Larson J. E., Wang X., Pearce K. H., Herring L. E., Graves L. M., Frye S. V., Emanuele M. J., Cox A. D. & Der C. J. (20200807). Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. : Science signaling.

Chicago

Blake Devon R, Vaseva Angelina V, Hodge Richard G, Kline McKenzie P, Gilbert Thomas S K, Tyagi Vikas, Huang Daowei, Whiten Gabrielle C, Larson Jacob E, Wang Xiaodong, Pearce Kenneth H, Herring Laura E, Graves Lee M, Frye Stephen V, Emanuele Michael J, Cox Adrienne D and Der Channing J. 20200807. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. : Science signaling.

Harvard

Blake D. R., Vaseva A. V., Hodge R. G., Kline M. P., Gilbert T. S. K., Tyagi V., Huang D., Whiten G. C., Larson J. E., Wang X., Pearce K. H., Herring L. E., Graves L. M., Frye S. V., Emanuele M. J., Cox A. D. and Der C. J. (20200807). Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. : Science signaling.

MLA

Blake Devon R, Vaseva Angelina V, Hodge Richard G, Kline McKenzie P, Gilbert Thomas S K, Tyagi Vikas, Huang Daowei, Whiten Gabrielle C, Larson Jacob E, Wang Xiaodong, Pearce Kenneth H, Herring Laura E, Graves Lee M, Frye Stephen V, Emanuele Michael J, Cox Adrienne D and Der Channing J. Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. : Science signaling. 20200807.